Therapeutic significance of ARID1A mutation in bladder cancer
1Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Centre - University of Freiburg, Freiburg, Baden-Württemberg, Germany.
Abstract:
Bladder cancer (BC) develops from the tissues of the urinary bladder and is responsible for nearly 200,000 deaths annually. This review aims to integrate knowledge of recently discovered functions of the chromatin remodelling tumour suppressor protein ARID1A in bladder urothelial carcinoma with a focus on highlighting potential new avenues for the development of personalised therapies for ARID1A mutant bladder tumours. ARID1A is a component of the SWI/SNF chromatin remodelling complex and functions to control many important biological processes such as transcriptional regulation, DNA damage repair (DDR), cell cycle control, regulation of the tumour microenvironment and anti-cancer immunity. ARID1A mutation is emerging as a truncal driver mutation that underlies the development of a sub-set of urothelial carcinomas, in cooperation with other driver mutations, to cause dysregulation of a number of key cellular processes. These processes represent tumour drivers but also represent potentially attractive therapeutic targets.
Insights
The ARID1A gene mutation drives bladder cancer by disrupting key cellular processes. Targeting these ARID1A-mutant bladder tumours may offer new personalized therapy options.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Bladder cancer (BC) is a significant cause of cancer mortality.
- ARID1A, a tumor suppressor protein, is involved in chromatin remodeling.
- ARID1A mutations are increasingly recognized in a subset of urothelial carcinomas.
Purpose of the Study:
- To review the functions of ARID1A in bladder urothelial carcinoma.
- To identify potential therapeutic targets in ARID1A-mutant bladder tumors.
- To explore personalized therapy strategies for ARID1A-mutant bladder cancer.
Main Methods:
- Literature review of recent studies on ARID1A.
- Analysis of ARID1A's role in SWI/SNF complex.
- Integration of knowledge on ARID1A's functions in cellular processes.
Main Results:
- ARID1A regulates transcriptional regulation, DNA damage repair (DDR), cell cycle, tumor microenvironment, and anti-cancer immunity.
- ARID1A mutations cooperate with other mutations to drive urothelial carcinoma development.
- Dysregulated cellular processes due to ARID1A mutation are potential therapeutic targets.
Conclusions:
- ARID1A is a critical tumor suppressor in bladder cancer.
- Understanding ARID1A's functions provides insights into urothelial carcinoma pathogenesis.
- Targeting ARID1A-mutant bladder tumors offers a promising avenue for personalized medicine.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation